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Three patients who developed clinical evidence of non-convulsive status epilepticus while on high doses of the 
investigational ntiepileptic drug, tiagabine are reported. This apparently paradoxical phenomenon developed 
when the tiagabine dose was increased to 48 mg/day in one patient, and to 60 mg/day in two other patients, in 
combination with other antiepileptic drugs. Seizure control improved following reduction in tiagabine dose in one 
patient and discontinuation of tiagabine in the two others. The observation raises the possibility of a clinically 
relevant paradoxical epileptogenic effect of GABA-ergic drugs such as tiagabine. 
INTRODUCTION 
Non-convulsive status epilepticus comprises 25% 
of all cases of status 1, with complex partial status, 
often regarded as a rare condition, being the most 
common in adults 2"3. Paradoxical exacerbation of
epilepsy by conventional antiepileptic drugs has 
been reported sporadically for at least the last 30 
years 4. Tiagabine, a nipecotic acid analogue, is an 
investigational antiepileptic drug which inhibits 
gamma amino butyric acid (GABA) neuronal 
and glial re-uptake. It is effective in patients with 
partial seizures, with or without secondarily 
generalized seizures and has only mild adverse 
effects on the central nervous ystem 5.There have 
been no reports of paradoxical aggravation of 
seizure control by tiagabine, either in the 
published literature or in reports to the phar- 
maceutical company. In this report we describe 
non-convulsive status epilepticus in three patients 
treated with tiagabine, in doses of 48 to 
60 mg/day, for refractory complex partial seizures 
in combination with two other antiepileptic drugs. 
CASE REPORTS 
The three patients reported here comprised three 
of the six patients who entered the open 
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continuation phase of a parallel arm design, 
double-blind, placebo-controlled, multicentre 
trial of tiagabine in 15 patients with refractory 
seizures. 
Case 1 
This 46-year-old man had experienced complex 
partial seizures from the age of 21 years. 
Electroencephalography showed bilateral an- 
terior sharp wave activity, mostly over the left 
temporal region, and foramen ovale recordings 
indicated lateralization of the left medial temp- 
oral lobe and secondary generalization. Tiagabine 
was added to the pre-existing combination of 
carbamazepine 400mg b.i.d., and lamotrigine 
200 mg b.i.d, when he was averaging five complex 
partial seizures a month. Subsequently, the 
patient's carbamazepine dose was reduced to 
400 mg daily when tiagabine was increased to 
14 mg t.i.d, and lamotrigine continued in a dose of 
400 mg daily. Carbamazepine was then progres- 
sively withdrawn, while tiagabine was increased 
to 16 mg t.i.d, in an attempt o limit lassitude. 
Three days later the patient was admitted to 
hospital when he became progressively confused 
and unresponsive, exhibiting aggressive be- 
haviour, repeated chewing activity and yawning, 
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as well as repeated falls. He was unaware of his 
surroundings for at least 3 hours on the day of 
admission. When admitted to hospital he exhib- 
ited stereotyped movements, was aggressive and 
uncooperative, using expletives. Following in- 
travenous administration of 10 mg of diazepam 
there was an instantaneous change, the patient 
becoming fully orientated in time, person and 
place, with cessation of involuntary movements 
and return of normal responsiveness. Subsequent 
physical and neurological examination was nor- 
mal. The patient remembered that he could not 
find the right words prior to admission when in his 
confused state, but the day after admission his 
speech was completely normal, although he did 
experience one secondarily generalized tonic- 
clonic seizure 20 hours after admission. He made 
an uneventful recovery and has remained well, 
experiencing his previous level of seizure fre- 
quency, continuing to take a lower dose of 
tiagabine, 14mg t.i.d., in combination with 
lamotrigine, 200mg b.i.d., and carbamazepine 
200 mg b.i.d. 
Case 2 
This 49-year-old man had a 41 year history of 
localization-related pilepsy, poorly controlled on 
previous antiepileptic drug therapy, most recently 
taking carbamazepine 400 mg t.i.d, and phenytoin 
350 mg daily. His seizures were characterized by 
an aura described as 'giving way' as well as by 
secondarily generalized convulsive seizures with 
deterioration in seizure control in the 3 months 
prior to his entering the open continuation phase 
of the tiagabine trial. The patient had a long 
standing left lower motor neurone facial weak- 
ness. The EEG recorded a left temporal slow 
wave abnormality and CT head scan showed 
cerebral and cerebellar atrophy. Tiagabine 10 mg 
t.i.d, was added to carbamazepine 400 mg t.i.d. 
and phenytoin 350 mg daily when his monthly 
seizure frequency ranged from two to six complex 
partial and secondarily generalized tonic-clonic 
seizures. The dose of tiagabine was subsequently 
increased in steps to 12 mg t.i.d., 16 mg t.i.d, and 
then to a total daily dose of 54 mg at which time 
his monthly seizure frequency was four. It was 
then further increased to 20 mg t.i.d, in combina- 
tion with carbamazepine 400mg t.i.d, and 
phenytoin 350 mg per day. Two weeks later the 
patient's wife noticed that he was unresponsive, 
with periods of staring blankly for up to one hour 
and recurrent episodes of disturbed balance and 
vision, following the increase in tiagabine dose to 
60mg per day. The patient subsequently ex- 
perienced three to four episodes of blank staring, 
with impaired awareness lasting up to 30 minutes, 
appearing to be in a world of his own, and there 
was a cluster of 3 secondarily generalized 
tonic-clonic seizures over the 3-4 weeks leading 
up to his admission to hospital, with twitching of 
the right side of his face and shaking of the right 
arm, held in a flexed position close to his chest. 
One week later the patient was admitted through 
the casualty department of a local hospital 
because of prolonged seizure activity for 4 hours 
during which he continued to stare into space for 
a few minutes followed by rigidity of his shoulder, 
holding his arms flexed in front of his chest and 
shaking. He appeared to respond to his wife at 
times, but at others was unresponsive and 
aphasic. His pupils were both dilated. This 
episode lasted two and a quarter hours until he 
was given diazepam 5mg intravenously, following 
which he became normally responsive but com- 
plained of tiredness with no memory of the 
preceding event. Tiagabine was progressively 
withdrawn over the ensuing week while the 
patient remained seizure-free in hospital and 
experienced only two partial seizures during the 3 
weeks after leaving hospital. He continued to 
take phenytoin 350 mg daily and carbamazepine 
400 mg t.i.d, and has remained well. 
Case 3 
This 19-year-old moderately retarded man had a 
ventricular haemorrhage in the perinatal period 
with subsequent hydrocephalus, requiring a 
ventriculo-peritoneal shunt. He had experienced 
generalized tonic-clonic seizures without any 
warning, at a frequency of approximately one per 
month all his life, with clusters of complex partial 
seizures occurring at weekly intervals. He was 
being treated with a combination of vigabatrin 
and lamotrigine when he entered a trial of the 
investigational drug, tiagabine. The patient was 
subsequently continued on open-label tiagabine, 
12mg three times daily, in combination with 
lamotrigine, 200 mg twice daily, and vigabatrin 
1500mg twice a day, at which time he was 
averaging 25 complex partial seizures per month. 
He experienced an episode of twilight state in 
May 1993, when he tookan accidental overdose 
of tigabine from which he made an uneventful 
recovery. Following an increase in tiagabine, 
from 48 mg/day to 60 mg daily, he experienced 12 
episodes of a trance-like state, lasting from 1 to 2 
hours during a 4 week period, commencing in 
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November 1993, whilst taking tiagabine, 20mg 
three times daily, in combination with lamotrigine 
200 mg twice a day and vigabatrin, 1500 mg twice 
daily. The patient's parents considered that they 
resembled the period following the accidental 
overdose of tiagabine several months previously. 
His parents noted that he returned to normal 
between the episodes and interictally the patient 
was found to have a normal general physical 
examination and normal neurological 
examination. 
DISCUSSION 
These three patients originally formed part of a 
multicentre parallel arm, placebo-controlled, 
double-blind trial of tiagabine versus placebo in 
15 patients, six of whom continued on the drug as 
part of an open dose-ranging trial. They had 
certain clinical features in common. They were all 
male with a long history of refractory localization- 
related epilepsy, taking other antiepileptic drugs 
in combination with tiagabine. All three patients 
experienced prolonged episodes of unresponsive- 
ness, a type of twilight state, during step-dose 
increases of tiagabine to maximum doses ranging 
between 48mg/day and 60mg daily. In two 
patients the seizure symptomatology was im- 
mediately terminated by parenteral ben- 
zodiazepine therapy and it did not recur in the 
third following progressive withdrawal of tiaga- 
bine. One patient has continued on tiagabine 
without any further twilight state episodes, but at 
a lower dose. In case 1, carbamazepine discon- 
tinuation, despite its cautious rate of withdrawal, 
could have lead to the increase in seizure 
frequency, associated with lack of adequate 
antiepileptic efficacy of the continuing drugs, 
namely tiagabine and lamotrigine, despite their 
continuation i  doses that would be expected to 
have antielpileptic efficacy. 
The following criteria have been recommended 
for the diagnosis of non-convulsive status epilep- 
ticus, namely, impaired consciousness or respon- 
siveness, without convulsions, for at least 60 
minutes, and concomitant seizure activity in the 
EEG entirely different from the interictal EEG 
pattern ~ and recurrent clinical seizures and 
continuous altered behaviour 2. No EEG was 
performed in these cases because the episodes 
resulted in out of hours admission. However, the 
clinical picture and response to intravenous 
diazepam in two of them, and the history from 
reliable eye witnesses in the third, were consistent 
with the diagnosis of non-convulsive status 
epilepticus 1-3. All the episodes of twilight state in 
these three patients occurred in the context of 
well documented epilepsy, implying that they 
were examples of complex partial status which is 
now being recognized with increasing 
frequency ~e. There was no previous history of 
episodes of complex partial status in any of the 
three. 
Paradoxical exacerbation of epilepsy by other 
antiepileptic drugs has been reported sporadically 
for at least the last 30 years 4. Increased seizure 
frequency and precipitation of status epilepticus 
has been reported for phenytoin 6-8. Exacerbation 
by carbamazepine has also been reported, par- 
ticularly in association with acute intoxication 2, 
and in children with recognized brain damage 9-1~. 
Characteristically, the seizures involved were 
mainly 'atypical' absences and minor motor 
seizures which increased in frequeficy a few days 
after carbamazepine was started and subsided 
following its discontinuation 4. 
Tiagabine, a nipecotic acid analogue, is an 
investigational ntiepileptic drug which inhibits 
gamma amino butyric acid (GABA) re-uptake. 
Its clearance is via hepatic metabolism, without 
production of active metabolites, with an elimi- 
nation half-life of 5-8 hours and plasma protein 
binding of 96%. Tiagabine does not induce 
hepatic enzyme activity, but its metabolism is 
enhanced by other enzyme-inducing drugs, re- 
ducing its elimination half-life to approximately 
2-4 hours. Sodium valproate displaces tiagabine 
from plasma protein binding sites, but tiagabine 
does not affect he kinetics of other antiepileptic 
drugs 5. Interactions with other antiepileptic drugs 
would not seem to explain our observations. 
Tiagabine is effective in patients with partial 
seizures, including secondarily generalized se- 
izures and only mildly adverse effects on the 
central nervous ystem have been recognized 5. To 
date, there have been no reports of paradoxical 
aggravation of seizure control, either in the 
published literature or reported to Novo Nordisk 
by Lassen (pers. comm.). 
In summary, we have reported three patients 
who developed prolonged episodes of twilight 
state, clinically consistent with non-convulsive 
status epilepticus, following progressive increase 
in tiagabine dose to between 48 and 60 mg/day. 
The aim of this report is to draw the attention of 
clinicians involved in treating patients with 
refractory epilepsy to the possibility that anti- 
epileptic drugs may produce paradoxical epilep- 
togenic effects, particularly in patients with 
certain types of refractory partial epilepsy, who 
are prone to seizure clustering. 
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